Results 251 to 260 of about 68,732 (285)

Cancer epigenetics in clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Veronica Davalos, Manel Esteller
exaly  

POSB270 Does Orphan Drug Status Confer Any Benefits for Products Undergoing HTA Appraisal By NICE in England?

Value in Health, 2022
G Foxon, P Craddy, C Wilson
openaire   +1 more source

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

The Orphan Drug Products—Another Solution?

Drug Intelligence & Clinical Pharmacy, 1983
openaire   +1 more source

Developments Related to Orphan Drug Products

American Journal of Health-System Pharmacy, 1983
openaire   +1 more source

New products highlight ambiguity of orphan drug law

Nature Biotechnology, 2003
openaire   +1 more source

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly  

Innovations in research and clinical care using patient‐generated health data

Ca-A Cancer Journal for Clinicians, 2020
H S L Jim, Aasha I Hoogland, Naomi C Brownstein   +2 more
exaly